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ABSTRACT
Objective: To study the anti-obesity potential of aqueous rhizome extract of Acorus calamus Linn. (AREAC) in high-fat diet (HFD) fed obese rats.
Methods: Adult strain male Wistar rats used in this study were fed with HFD for 60 days. For the treatment groups, AREAC was administered in a dose 
levels of 100, 200, and 300 mg/kg bw, orally once a day along with HFD. Rats fed with normal pellet chow were served as normal control. The effect 
of AREAC on physical parameters such as body weight, organ weight, fat pad weights, and various biochemical parameters such as serum glucose, 
insulin, leptin, lipid profile, liver markers, kidney markers, and oxidative stress markers were analyzed. In vitro pancreatic lipase inhibition assay of 
AREAC was also studied.
Results: Data of in vivo studies revealed significant (p<0.05) reduction in percentage body weight gain, organ weights, fat pad weights and levels 
of serum glucose, insulin, and leptin after treatment with AREAC in a dose-dependent manner. Furthermore, administration of AREAC significantly 
inhibited the increases in the concentrations of triglycerides, total cholesterol, low-density lipoprotein-cholesterol, very low-density lipoprotein-
cholesterol, free fatty acid, and phospholipids in a dose dependent manner whereas, the level of high-density lipoprotein-cholesterol was found to be 
elevated on treatment. Moreover, on treatment with a test drug, the elevated levels of serum liver and kidney markers such as aspartate transaminase, 
alanine transaminase, alkaline phosphatase, urea, and creatinine were also brought back to near normalcy. Antioxidant status was found to be 
enhanced in liver tissues after treatment. In vitro studies showed significant inhibition in the activity of pancreatic lipase by AREAC.
Conclusion: The data of the results obtained clearly depicted that AREAC was found to have pronounced anti-obesity activity particularly at the dose 
levels of 300 mg/kg bw.
Keywords: Obesity, High fat diet, Leptin, Acorus calamus Linn., Orlistat.
INTRODUCTION
Obesity is a medical condition in which excess fat has been accumulated 
in the body. This metabolic disorder is resulting from a chronic 
imbalance between energy intake and expenditure [1]. A net excess of 
energy, caused by either, greater intake or lesser expenditure, results in 
exaggeration of the adipose tissue, and weight gain. Body mass index 
(BMI), a measurement which compares weight and height, defines 
people as overweight (pre-obese) when their BMI is between 25 and 
30 kg/m2, and obese when it is >30 kg/m2.
Obesity is a serious health problem. It is associated with increased 
risk for numerous medical problems and health hazards, including 
hypertension, dyslipidemia, coronary heart disease, type 2 diabetes, 
gallbladder disease, sleep apnea, osteoarthritis, and various forms of 
cancer [2]. For example, the prevalence of hypertension is 2.9 times 
greater among overweight adults compared to their nonoverweight 
peers. Overweight women experience substantially greater risk for 
all-cause and some cause-specific mortality than leaner women [3]. 
Obesity also is associated with increased health and socioeconomic 
costs (e.g., hospital care, physician’s services, and medications, 
productivity changes related to illness, and death). Yearly, an estimated 
300,000 deaths are directly due to being overweight or obese. In one 
study, it was estimated that overweight individuals have a decreased 
life expectancy of 3 years, while obese individuals have a life expectancy 
deficit of 7.1 years for females and 5.8 years for males [4].
An alarming rate of obesity prevalence has been observed globally 
over the last 30 years independent of age, sex, race, socioeconomic 
status, profession, etc., creating a serious health concern and also 
becoming an epidemic of the 21st century. It is estimated that there 
were over one billion of overweight individuals and more than 300 
million who are obese. Childhood obesity is also rapidly emerging as 
one of the greatest global challenges of the 21st century. Worldwide, 
the prevalence of childhood overweight and obesity increased from 
4.2% in 1990 to 6.7% in 2010. This trend is expected to reach 9.1%, 
in 2020 [5].
Obesity is mainly associated with modern lifestyle, for this, the modern 
medicine has little to offer. Routine medical treatment of obesity 
consisting of nutrition education, behavior modification, exercise 
therapy, and activity training was reported to have a failure rate of 
about 85% over 5-10 year when treatment was not continued [6]. 
Pharmacological interventions for obesity have produced modest 
and temporary reductions in weight, but have been associated all too 
frequently with aversive side effects and health risks [7]. Massively 
obese patients who meet the criteria for obesity surgery achieve long-
term weight loss in a good percentage of cases, but post-operative 
complications are the worrying concern.
The obesity epidemic, along with its associated comorbidities and the 
discouraging results of the current treatment methods points out the 
absolute necessity of safe and effective alternative therapy. Ayurvedic 
system of medicines is one of the oldest systems of medicine having a 
history of more than 5000 years. Several prototypes derived from these 
herbal medicines are in use for various kind of disease and disorders 
including obesity. More than 50% of modern drugs existing in clinical 
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use for various ailments today are derived from natural products such 
as plants [8,9].
In this work also attempts have been made to develop an eco-
friendly and efficacious plant drug for managing obesity through 
scientific evaluation of the anti-obesity potential of aqueous 
rhizome extract of a common, well known medicinal herb Acorus 
calamus L. belonging to the family Araceae through in vitro and in 
vivo approaches.
METHODS
Collection, identification, and authentication of plant material
Plant source selected for this study (rhizome of Acorus calamus Linn.) 
was collected freshly from farmland at Nagapattinam and identified with 
the help of Flora of Presidency of Madras [10] and was authenticated 
with the help of herbarium specimen deposited at Rapinat Herbarium, 
St. Joseph’s College, Trichy, Tamil Nadu, India.
Preparation of plant extract
After proper identification, the selected plant source was cleaned, shade 
dried, and coarsely powdered. The granulated powder of the selected 
herb was mixed thoroughly with six times the volume of water, boiled, 
and stirred continuously until the volume reduced to 1/3rd. The extract 
was then filtered using a muslin cloth, and the filterate was evaporated 
in a water bath until it reaches a thick paste consistency. A paste form 
of the extracts obtained was stored in an airtight container at 4°C for 
further use.
Experimental animals
Healthy adult Wistar strain male albino rats weighing around 
150-200 g obtained from Tamil Nadu Veterinary and Animal Sciences 
University, Chennai were used for this study. The animals were housed 
in polypropylene cages under controlled environment (12:12 - hrs 
light/dark cycle; an ambient temperature of 23±2°C with 65±5% 
humidity) with free access to standard rat chow pellet (obtained from 
Sai Durga Foods and Feeds, Bengaluru, India) and water ad-libitum. 
The animals were acclimatized to the laboratory conditions for a week 
before experiments.
All the studies were conducted according to the ethical guidelines 
of CPCSEA after obtaining necessary clearance from the committee 
(Approval No: 790/03/ac/CPCSEA).
Induction of obesity
Obesity was induced in albino rats of normal weight by feeding 
them a high-fat cafeteria diet. The cafeteria diet [11] contain three 
diets - (a) condensed milk (48 g)+bread (48 g), (b) chocolate 
(18 g)+biscuits (36 g)+dried coconut (36 g), and (c) cheese (48 g)+boiled 
potato (60 g). The three diets were presented to the individual rats on 
days one, two, and three, respectively, and then repeated for 60 days in 
the same succession.
Experimental design
Adult Wistar strain albino rats were divided into six groups of six rats 
each:
Group I: Normal control - Rats fed with normal rat chow.
Group II: Obese control - Rats fed with high-fat diet (HFD) for 60 days.
Group III:  Rats fed with HFD+treated with aqueous rhizome extract of 
Acorus calamus (AREAC) at a dose level of 100 mg/kg body 
weight, once a day orally for 60 days.
Group IV:  Rats fed with HFD+treated with AREAC at a dose level of 
200 mg/kg body weight, once a day orally for 60 days.
Group V:  Rats fed with HFD+treated with AREAC at a dose level of 
300 mg/kg body weight, once a day orally for 60 days.
Group VI:  Rats fed with HFD+treated with the reference drug orlistat at a 
dose level of 50 mg/kg body weight, once a day orally for 60 days.
At the end of the experimental period of 60 days, the animals were 
sacrificed by cervical decapitation after a 12 hr fast. Blood was 
collected and used for various biochemical estimations. Heart, liver, 
kidney, spleen, and the fat pads were excised, weighed and processed 
for biochemical analysis. Histopathological studies of liver, heart, and 
kidney tissues were carried out. Liver tissues were homogenized, in 
0.1 M phosphate buffer, pH 7.4 and were used for analyzing various 
biochemical parameters.
In vitro pancreatic lipase inhibition assay [12] of AREAC was also 
analyzed in addition to this in vivo study.
Statistical analysis
All the results were expressed as mean±standard error of the mean. 
The data were statistically analyzed by one-way analysis of variance.
RESULTS
Pancreatic lipase inhibitory activity of AREAC
The anti-lipase activity of AREAC was tested, and the obtained results 
are shown in Fig. 1.
Effect on daily food intake
The daily food intake of experimental rats treated with AREAC was 
measured, and the obtained results are shown in Fig. 2. The data 
reveals slight decrease in food intake in AREAC treated group rats than 
obese control rats, but not much difference was observed between 
Group III, IV, and V animals. This result suggested that AREAC treatment 
does not influence the daily food intake.
Effect on body weight
The changes in the body weight of the experimental animals were 
recorded on day 1 and at a regular interval of 10 days, and the data 
were graphically represented in Fig. 3. The obtained results clearly 
shows a significant reduction in the body weight of the obese rats in a 
dose dependent manner when treated with different dose levels (100, 
200, and 300 mg/kg bw) of AREAC.
Effect on fat pad and organ weights
The effect of treatment of obese rats with AREAC on weight of fat pad 
(such as mesenteric, retroperitoneal, and perirenal) and organs (such 
as liver, kidney, and spleen) are presented in Figs. 4 and 5, respectively. 
The weights of fat pads and organs were increased in HFD fed obese 
control animals while treatment with plant extract showed decrease in 
the weights of fat pads and organs.
Effect on glucose, insulin, and leptin levels
The effect of treatment of obese rats with AREAC on blood glucose, 
serum insulin, and leptin levels in the experimental animals are given 
in Table 1. The elevated levels of blood glucose, insulin, and leptin in 
HFD fed obese rats were restored to near normalcy on treatment with 
plant extract.
Effect on serum and hepatic lipid profile
The effect of AREAC on serum lipid profile was shown in Table 2. 
Administration of HFD to the experimental animals resulted in the 
Fig. 1: The inhibitory effect of aqueous rhizome extract of Acorus 
calamus on pancreatic lipase activity
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elevated levels of serum triglyceride (TG), total cholesterol (TC), 
low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), 
atherogenic index (AI), phospholipids (PL), and free fatty acids (FFAs) 
while high-density lipoprotein-cholesterol (HDL-C) was found to be 
decreased. Hepatic TG and TC levels were also elevated in HFD fed 
rats. Oral administration of different dose levels of aqueous extracts of 
selected plant drug to the obese rats efficiently restored these altered 
lipid profiles to normal. The effect was statistically significant (p<0.05) 
and dose dependent.
Effect on liver and kidney markers
The levels of liver marker such as alanine transaminase (ALT), aspartate 
transaminase (AST), and alkaline phosphatase (ALP) were elevated 
while protein level was decreased in serum of HFD fed rats when 
compared to normal rats. Upon treatment with AREAC these alterations 
were normalized in a dose-dependent manner. Elevated levels of kidney 
markers such as urea and creatinine in HFD fed rats were also brought 
back to normal in a dose dependent manner on treatment with AREAC 
(Table 3).
Effect on enzymatic and nonenzymatic antioxidant status in liver
The effect of AREAC on enzymatic and nonenzymatic antioxidant status 
in hepatic tissues is given in Table 4.
DISCUSSION
Obesity is a health problem of epidemic proportions in the industrialized 
world. It is associated with an increased risk of life-threatening 
pathologies such as diabetes, hypertension, and heart diseases. The 
obesity epidemic in the world today, warrants increasing awareness and 
need to improve the quality and effectiveness of available treatments. 
The long-term effectiveness of the existing lines of treatment for 
obesity such as lifestyle modification or pharmacotherapy is not 
satisfactory. Moreover, the side effects associated with the modern 
pharmacotherapy forced the suffering mankind to resort to better, long 
lasting and safe therapy. Herbal supplements and diet-based therapies 
for the management of obesity are preferable among the most common 
complementary and alternative medicine. Hence in this study, the 
antiobesity potential of AREAC was evaluated in HFD induced obese 
rats through in vitro and in vivo analysis.
Pancreatic lipase is the most important enzyme for the digestion of 
dietary triacylglycerols (TAGs). It is well known that dietary fat is not 
directly absorbed from the intestine unless it has been subjected to the 
action of pancreatic lipase [13]. The application of pancreatic lipase 
inhibitor was examined earlier as a treatment for diet-induced obesity 
in humans. It has been clinically reported that a pancreatic lipase 
inhibitor orlistat prevented obesity and hyperlipidemia through the 
increment of fat excretion into faeces and the inhibition of pancreatic 
lipase. In this study, it was found that AREAC inhibited the pancreatic 
lipase activity significantly and the effect was comparable to that of 
the positive control, orlistat. IC50 value of the extract was found to be 
248.7 µg/ml.
A gain in body weight is a common index of obesity development. HFD 
feeding resulted in approximately 69.37% increase in body weight of 
Fig. 2: Effect of aqueous rhizome extract of Acorus calamus on 
food intake in experimental rats
Fig. 3: Effect of aqueous rhizome extract of Acorus calamus on 
percentage body weight gain in experimental rats
Fig. 4: Effect of aqueous rhizome extract of Acorus calamus on 
fat pad weights in experimental rats. Values are mean±standard 
error of the mean of 6 rats
Fig. 5: Effect of aqueous rhizome extract of Acorus calamus on 
organ weights in experimental rats. Values are mean±standard 
error of the mean of 6 rats









Group I 74.83±0.88 3.34±0.11 2.97±0.08
Group II 146.96±1.14# 7.23±0.18# 6.86±0.1#
Group III 130.07±1.13 6.97±0.18 5.91±0.19
Group IV 99.93±1.4 4.78±0.22 4.25±0.13
Group V 86.85±0.98* 3.98±0.13* 3.60±0.2*
Group VI 74.15±1.15* 3.87±0.15* 3.11±0.12*
Values are mean±SEM of 6 rats. #p<0.01 versus normal control; *p<0.05 versus 
obese control. SEM: Standard error of the mean, AREAC: Aqueous rhizome 
extract of Acorus calamus
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the rats in a period of 60-day. This weight gain was around 47% more 
as compared to normal control animals. Consumption of HFD led to 
obesity because it facilitated the development of a positive energy 
balance leading to an increase in visceral fat deposition. In this study, it 
was found that the administration of AREAC along with HFD displayed 
significant reduction (p<0.05) in weight gain in a dose-dependent 
manner when compared to the HFD alone fed rats. These inhibitions 
in weight are not due to decreased food or energy intake as there was 
no significant difference in the amount of food consumed between the 
high-fat diet and plant extract treated groups (Fig. 2). This observation 
also indicated that dietary factors other than energy intake play an 
important role in body weight regulation. Reduction in body weight 
may partially be mediated via the inhibition of pancreatic lipase and 
partially may via the activation of thermogenesis by phytoconstituents 
through the stimulation of the β-adrenergic receptors. Yun, 2010 
reported that some flavonoids activate β-adrenergic receptors which 
are involved in the burning of fats [14].
Adipose tissue is vital for maintaining whole body energy homeostasis 
and it consists of adipocytes, which store TAG as a fuel for the body. 
Excessive adipose tissue deposition is attributed to an imbalance 
between energy intake and energy expenditure [15]. Adipose tissue is 
accumulated as fat pads. Therefore, measuring the weight of these fat 
pads provided an insight about the severity of obesity. It was found that 
the weights of the mesenteric, retroperitoneal, and perirenal adipose 
tissue deposits were significantly higher in the HFD fed rats than the 
normal diet fed rats. While, treatment with AREAC significantly (p<0.05) 
reduced the weights of fatty deposits at the mesenteric, intraperitoneal, 
and perirenal regions as compared to that of HFD group.
The gain in organ weight such as liver, kidney, and spleen can be 
also used as an index of obesity because intake of excess energy 
led to accumulation of extra energy in adipose tissues followed 
by accumulation of the same in organs such as liver, kidney, and 
spleen [16]. HFD feeding resulted in an increase in the weight of all 
these organs, i.e., liver, kidney, and spleen by approximately 56%, 71%, 
and 80%, respectively. However, the plant extract reduced the observed 
gains in organ weights in a dose-dependent manner.
Insulin is a hypoglycemic hormone which mediates the uptake of 
glucose by cells which are used for energy. In obesity, however, insulin 
signaling is defective due to insulin resistance and is the major cause 
of type 2 diabetes mellitus. Insulin resistance or glucose intolerance 
in obesity condition may be attributed partly for the concomitant 
increases in circulating FFAs in the blood stream [17].
Due to defective insulin signaling glucose cannot be transported into 
the muscle or liver cells hence leads to hyperglycemia. In responsive to 
hyperglycemia, pancreatic β-cells continually synthesize insulin which 
in turn leads to hyperinsulinemia. Hyperinsulinemia, hyperglycemia 
and insulin resistance are frequently associated with human 
obesity [18]. Our results also showed significant (p<0.05) increase in 
the levels of serum glucose and insulin in HFD fed rats when compared 
to normal diet fed rats. However, rats administered AREAC along with 
HFD showed significant (p<0.05) decrement in the levels of serum 
glucose and insulin. The hypoglycemic and hypoinsulinemic effect was 
dose dependent and this hypoglycemic and hypoinsulinemic effect may 
be mediated by the active phytoconstituents present in the test drug 
through increased adiponectin secretion, suppressed tumor necrosis 
factor-alpha secretion in white adipose tissue, and increased GLUT4 
expression in skeletal muscle.
Leptin is synthesized and secreted mainly by adipose tissue in 
approximate proportion to fat stores. Circulating leptin communicates 
the level of energy reserves in the periphery to the central nervous 
system to suppress food intake and to permit energy expenditure. 
However, elevated concentrations of endogenous leptin do not appear 
to be capable of preventing, or reversing, the accumulation of adipose 
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reported that the consumption of a HFD results in the development of 
leptin resistance in rodents [19,20]. This is measured as a failure of 
leptin either to inhibit food intake or to induce weight loss as observed 
in this study (Table 1). Increased circulating leptin, a marker of 
leptin resistance, is common in obese condition and is independently 
associated with insulin resistance and cardio vascular diseases in 
humans [21].
In general, all lipids are absorbed into the blood in the gastrointestinal 
tract in the form of chylomicrons, composed of TGs, PL, cholesterol, 
and apolipoprotein B. The TGs in these chylomicrons are then digested 
as fatty acids and glycerol by lipoprotein lipase. These fatty acids are 
transported and stored in liver and adipose tissues in the form of 
TGs. The remnants of the chylomicrons are mainly taken up by liver, 
and then transformed into several lipoproteins containing TGs, PL, 
cholesterol, and apolipoproteins. As a result, increased intake of lipids 
in food causes not only an accumulation of body fat, but also increases 
cholesterols, PL, and FFAs in the bloodstream. Furthermore, excess 
carbohydrates and proteins in the body are converted to TGs, which 
are the main fats stored in adipose and liver tissues [22]. All of these 
cause obesity and obesity-derived cardiovascular diseases, such as 
hyperlipidemia and atherosclerosis.
Increased levels of TGs, TC, LDL-cholesterol (LDL-C), VLDL-cholesterol 
(VLDL-C), FFA, PL and, decreased levels of HDL-C obtained in HFD 
fed rats confirmed that HFD intake induced obesity experimentally. 
In contrast, administration of AREAC along with HFD significantly 
(p<0.05) inhibited the increases in the concentrations of TG, TC, LDL-C, 
VLDL-C, FFA, and PL in a dose-dependent manner. The level of HDL-C 
was found to be elevated after treatment (Table 2).
A substantial reduction of TC in serum by AREAC could be attributed 
by reduction in the activities of the liver enzyme 3-hydroxy-3-
methylglutaryl coenzyme A reductase, which is a rate-limiting enzyme 
in cholesterol biosynthesis. Furthermore, a significant reduction in 
LDL-C and TC level in serum could be achieved by decreased production 
of TC by liver tissue and/or efficient removal of the LDL-C by various 
tissues without subsequent renewal [16]. Reductions in FFA, TG, and PL 
in serum could be attributed to the inhibition of lipid absorption in the 
gastrointestinal tract, through the inhibition of lipid digestive enzymes 
like pancreatic lipase in the GI tract. In vitro studies revealed significant 
inhibition (p<0.05) in the activity of pancreatic lipase by AREAC 
(Fig. 1). Studies have illustrated the beneficial effects of saponins on 
blood cholesterol levels. Saponins cause a depletion of body cholesterol 
by preventing its reabsorption, thus increasing its excretion, in a similar 
way as other cholesterol – lowering drugs, such as cholestyramine [23]. 
Therefore, the significant decrease (p<0.05) in serum cholesterol may 
also be attributed to the effect of the phytochemicals such as saponins 
present in the AREAC. A higher content of HDL-C is very important in 
humans because it is correlated with a reduced risk of coronary heart 
disease. The increased HDL facilitates the transport of cholesterol from 
the serum to the liver, where it is catabolized and excreted from the 
body.
The AI, defined as the ratio of TC and HDL-C, is believed to be an 
important risk factor of atherosclerosis. The data of this study clearly 
demonstrated that administration of AREAC significantly decreased 
the ratio. The effect was dose dependent and showed a maximum 
reduction at 300 mg/kg bw. It has been proven that abnormally high 
serum levels of TC and low serum levels of HDL-C are associated with 
an increased atherosclerosis risk. Increasing the HDL-C concentrations 
and decreasing the TC concentrations in HFD-fed rats indicates the 
antiatherogenic property of AREAC.
The liver is the central organ for cholesterol, phospholipid, TAG, and 
lipoprotein metabolism. In obesity, the liver is the receiver of large 
amounts of fatty acids, which cause its steatosis. Although the exact 
mechanism remains unclear, the pathogenesis of fatty liver (steatosis) 
is multifactorial, and it has been suggested that the presence of 
insulin resistance is an essential requirement for the accumulation 
of hepatocellular fat. It is postulated that insulin resistance results in 
combination of elevated plasma concentrations of glucose and fatty 
acids which leads to increased hepatic fatty acid synthesis, impaired 
β-oxidation, and hepatic steatosis [24]. The data of this study indicated 
that intake of HFD for 9 weeks elevated the levels of hepatic TGs and 
cholesterol indicating fatty liver. While administration of AREAC 
along with HFD suppressed the increased levels of hepatic TGs and 
cholesterol induced by HFD in a dose-dependent manner. This shows 
the amelioration of fatty liver. The lipid lowering actions of test drug 
may be due to increased expression of energy expenditure-related 
Table 3: Effect of AREAC on levels of liver and kidney markers in experimental rats
Experimental groups ALT (IU/dL) AST (IU/dL) ALP (IU/dL) Protein (g/dL) Urea (mg/ml) Creatinine (mg/ml)
Group I 69.03±1.29 40.89±1.34 69.75±1.45 6.59±0.12 16.98±0.36 0.63±0.01
Group II 145.99±1.74# 74.33±1.58# 148.11±1.8# 4.24±0.07# 40.39±0.84# 1.10±0.05#
Group III 133.46±1.3 62.36±1.57 128.06±1.87 4.42±0.1 31.94±0.51 1.02±0.02
Group IV 95.53±1.86 51.33±1.4 93.8±1.37 4.74±0.06 24.24±0.49 0.86±0.02
Group V 82.13±1.47* 47.72±0.84* 88.03±1.8* 4.91±0.05* 20.07±0.45* 0.78±0.02*
Group VI 74.72±1.34* 44.1±1.18* 75.09±1.36* 6.37±0.1* 18.14±0.51* 0.67±0.02*
Values are mean±SEM of 6 rats. #p<0.01 versus normal control; *p<0.05 versus obese control. SEM: Standard error of the mean, AREAC: Aqueous rhizome extract of 
Acorus calamus, ALT: Alanine transaminase, AST: Aspartate transaminase, ALP: Alkaline phosphatase



























Group I 86.01±0.92 4.52±0.15 157.88±1.94 3.61±0.09 4.89±0.15 29.15±1.09
Group II 147.01±1.43# 2.35±0.08# 88.26±1.56# 1.13±0.05# 1.85±0.06# 13.89±0.73#
Group III 129.91±1.42 2.71±0.07 101.09±1.74 1.36±0.04 2.41±0.05 17.8±0.36
Group IV 103.42±1.69 3.88±0.11 131.18±2.35 2.82±0.08 3.63±0.08 23.28±1.03
Group V 97.59±1.56* 4.17±0.09* 143.22±2.63* 3.11±0.1* 4.28±0.07* 25.03±0.44*
Group VI 92.67±0.74* 4.47±0.07* 156.56±2.27* 3.42±0.09* 4.61±0.15* 28.04±0.62*
Values are mean±SEM of 6 rats. #p<0.05 versus normal control; *p<0.05 versus obese control. LPO: Lipid peroxidation, SEM: Standard error of the mean, 
AREAC: Aqueous rhizome extract of Acorus calamus, MDA: Malondialdehyde, GSH: Glutathione
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genes in liver and decreased fatty acid synthesis and fat intake in the 
liver.
Obesity-related liver dysfunction falls within the abnormalities 
pertaining to the complex spectrum of non-alcoholic fatty liver 
disease (NAFLD). In the two-hit model of NAFLD pathogenesis, insulin 
resistance plays a pivotal role in determining the first hit: Steatosis. This 
increases the sensitivity of the liver to the second hits responsible for 
progression of liver disease and to hepatic necroinflammatory damage. 
Second hits involve oxidative stress resulting from an imbalance 
between pro-oxidant and antioxidant processes in the liver [25]. In this 
study, the levels of hepatic marker enzymes such as ALT, AST, and ALP 
were found to be elevated in the serum of HFD fed rats as compared 
to normal control. Such increases in enzymes may attribute to fatty 
liver and hepatic necroinflammatory injury induced by a high-fat 
diet. Whereas, the elevated levels of hepatic marker enzymes were 
significantly (p<0.05) diminished in the AREAC treated animals in a 
dose-dependent manner (Table 3). The decreased levels of ALP, AST, 
and ALT in the test drug-treated rats suggested the amelioration of fatty 
liver. The improvement of liver functions might be the outcome of the 
improved obesity condition due to the inhibitory effect of AREAC on 
pancreatic lipase activity. On the other hand, it is known that tannins 
(polyphenols) possess antioxidative activity, and proven antioxidants, 
such as β-carotene, vitamin E, and astaxanthin, might cause decrease in 
plasma transaminase levels as a result of prevention against oxidative 
damage [26]. Thus, there is also a possibility that the antioxidant 
efficacy of selected plant drug (AREAC) contributed to the decrement 
of elevated plasma transaminase levels.
The protein content was decreased significantly in rats administered 
with HFD as compared to the normal control animals. A healthy liver 
is so crucial for protein metabolism since liver disease is frequently 
associated with alterations in proteins and disturbances of protein 
metabolism [27]. The decrement in protein content may be due to 
their inadequate synthesis by liver in disease condition. However, after 
treatment with aqueous plant extract, the levels of protein raised to 
normal in a dose-dependent manner.
The obese rats showed a highly significant (p<0.05) increase in the 
concentration of serum urea and creatinine as compared to the normal 
group which is in agreement with the results of Cindik et al., 2005 [28]. 
These increases are attributed to damaged kidneys induced by excess 
accumulation of fat. Several mechanisms may contribute to the onset 
and or toward the progression of kidney damage/lesions in patients 
or animals suffering from obesity. Among them, lipid peroxidation 
and oxidative stress, high glucose levels, and glycated products, have 
been frequently proposed [29]. HFD induces alteration of renal 
lipid metabolism by causing an imbalance between lipogenesis and 
lipolysis in the kidney, as well as systemic metabolic abnormalities and 
subsequent renal lipid accumulation leading to renal injury [30]. Rats 
treated with AREAC showed decreased levels of urea and creatinine 
in serum in a dose-dependent manner. This decrement in the level of 
kidney markers indicated the amelioration of kidney damage and this 
protective effect might be mediated by the antioxidant molecules in the 
test drug by decreasing the oxidative stress through reduced LPO and 
improved blood lipid profiles and glucose levels.
An elevated metabolism during obesity results in increased production 
of free radicals or reactive oxygen species (ROS). These free radicals 
have an unpaired electron, which causes them to attack and capture 
electrons from other substances such as membrane lipids, nucleic acids, 
proteins, enzymes, and other small molecules to neutralize themselves. 
Although the initial attack causes the free radical to become neutralized, 
another free radical is formed in the process, causing a chain reaction 
to occur. Until subsequent free radicals are deactivated, thousands of 
free radical reactions can occur within seconds of the initial reaction 
leading to cellular damage. Thus, cells under aerobic condition are 
always threatened with the insult of ROS, which however are efficiently 
taken care of by the highly powerful antioxidant systems of the cell. 
Whenever, the balance between ROS production and antioxidant 
defence is lost, “oxidative stress” results which through a series of 
events deregulate the cellular functions leading to various pathological 
conditions including atherosclerosis, cancer, and hypertension. This 
oxidative stress is one of the key mechanism underlying obesity-related 
morbidities [31].
In liver cells, increased rate of metabolism and accumulation of fat 
(fatty liver) during obesity leads to the generation of large amount of 
ROS which in turn is vulnerable to LPO and oxidative stress. LPO is a 
free radical-generating process which occurs on every membranous 
structure of the cell [32]. Malondialdehyde (MDA), the product of LPO, is 
an index of the level of oxygen free radicals. The content of MDA in rats 
fed with HFD was significantly increased in liver tissues as compared 
to rats fed with standard laboratory diet, suggesting that obesity could 
enhance the process of LPO. Administration of AREAC prevented the 
HFD induced elevation of MDA and resulted in a significantly decreased 
content of MDA in liver.
Glutathione (GSH), a powerful antioxidant present within the cytosol, 
directly quenches ROS such as lipid peroxides and plays a major role 
against inflammatory response and oxidative stress. GSH also acts 
as substrate for glutathione peroxidase (GPx) and glutathione-S-
transferase (GST). The level of GSH in liver was significantly depleted 
in HFD fed animals when compared to normal control animals. This 
depletion of GSH in HFD fed animals may be due to its utilization in 
large amounts to combat the HFD induced oxidative damage, as GSH 
is a major non-protein thiol in living organisms playing a crucial role 
in coordinating the body’s antioxidant defence processes [33]. In the 
AREAC treated animals the level of GSH was significantly (p<0.05) 
restored.
Glutathione reductase (GR) is a flavoprotein enzyme, regenerates 
GSH from oxidized GSH in the presence of NADPH. It was found that 
the activity of GR was decreased in liver tissue of the HFD fed obese 
rats when compared to normal control rats. This might be due to 
decreased intracellular levels of NADPH-mediated by hyperglycemia. 
Hyperglycemia in the HFD group activates polylol pathway and inhibits 
pentose phosphate pathway resulting in decreased intracellular levels 
of NADPH, which is required for regeneration of GSH from its oxidized 
form GSSG. The net result was nonenzymatic disruption of H2O2 and 
increased levels of cellular superoxides, hydroperoxides, hydroxyl 
radicals as well as other radicals.
GPx is a major peroxide scavenging enzyme. In HFD fed obese rats, a 
fall in the activity of GPx was observed and this might be due to the 
depletion of GSH as GSH is directly involving in quenching the ROS in 
addition to, acts as a substrate for the detoxification of H2O2 by GPx. 
Administration of test drug effectively restored the activity of GPx and 
thereby decreased the production of hydroxyl radicals.
During oxidative damage of liver, superoxide radicals are generated 
at the site of damage and modulate superoxide dismutase (SOD) and 
catalase (CAT) resulting in the loss of activity and, accumulation of 
superoxide radical, which damages organs further. SOD and CAT are 
the most important enzymes in ameliorating the effects of oxygen 
metabolism. SODs are a family of endogenous antioxidant enzymes 
which act as the first line of defence system against ROS and are 
important in the catalytic decomposition of the superoxide radical into 
oxygen and hydrogen peroxide while CAT are enzymes that catalyze the 
conversion of hydrogen peroxide to water and oxygen. In the present 
study, the activities of SOD and CAT are decreased in HFD fed obese 
control rats as compared to normal control rats and this decrement 
might be due to generation of excessive free radicals and increased LPO. 
The activities of SOD and CAT were restored in the test drug-treated 
group rats. Overall, AREAC administration showed better effect on 
antioxidant levels or activity and this might be due to the involvement 
of natural antioxidant such as flavones present in the plant extract, in 
free radical scavenging process.
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CONCLUSION
Overall, the data of the results obtained clearly depicted that AREAC 
possesses pronounced anti-obesity activity particularly at the dose 
levels of 300 mg/kg bw. Furthermore, the data of the results observed 
in AREAC treated groups were in par with that of standard drug 
orlistat. As observed in this study, the anti-obesity potentials of the 
selected plant drug might probably be mediated through delayed 
intestinal absorption of dietary fat due to the inhibition of pancreatic 
lipase activity, enhancement of antioxidant status mediated by the 
antioxidants such as flavones and activation of the leptin signaling 
pathway.
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